Drug: ERYTHROPOIETIN ALFA, EPO (Epogen, Procrit)
Classification: Hematopoietic hormone
Indication: Treatment of neutropenia or anemia secondary to ZDV- or Ganciclovir-induced bone marrow suppression (most effective in patients with endogenous EPO levels < 500 IU/ml).
Dose: 100-250 U/kg 3 times/week, IV or SC.; do not shake bottle. Time to response: 2-8 weeks. Titrate frequency of dosage downward for maintenance after anemia is corrected. Hold dose if Hct>36%, until Hct begins to fall, then reinstitute at a lower dosage.
Side Effects: Uncontrolled hypertension, albumin intolerance.
Use in Pregnancy: Category C. Risk to fetus cannot be ruled out. Use if benefit outweighs potential risk.
Drug Interactions: none known
Monitoring: Check Hct at least 2 x/week after dose adjustment, for 2-6 weeks. CBC, B/P